Bulk Pharmaceutical API Sources for LENALIDOMIDE

Bulk Pharmaceutical API Sources for LENALIDOMIDE

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-848-370
Hangzhou APIChem Technology		AC-914
AKos Consulting & Solutions		AKOS005146276
Vitas-M Laboratory		STK639603
AKos Consulting & Solutions		AKOS005174869
Amadis Chemical		A813515

LENALIDOMIDE BULK API SOURCING ANALYSIS

Last updated: February 19, 2026

This report analyzes the global landscape of bulk active pharmaceutical ingredient (API) suppliers for lenalidomide, focusing on manufacturers with demonstrated production capacity, regulatory compliance, and market presence. The analysis identifies key API producers, their geographical distribution, and their engagement with major pharmaceutical markets.

WHAT ARE THE PRIMARY GEOGRAPHIC SOURCES FOR LENALIDOMIDE API?

The production of bulk lenalidomide API is concentrated in specific regions, reflecting established pharmaceutical manufacturing hubs and regulatory environments.

• India is a significant global supplier of lenalidomide API. Numerous Indian manufacturers have developed expertise in the synthesis of complex molecules, including immunomodulatory drugs like lenalidomide. These companies often benefit from lower manufacturing costs and a well-developed generic pharmaceutical industry.
• China also plays a crucial role in the global API supply chain for lenalidomide. Chinese manufacturers have scaled production capabilities and are increasingly investing in quality control and regulatory compliance to meet international standards.
• Europe has a presence in lenalidomide API manufacturing, although at a smaller scale compared to Asia. European manufacturers often focus on high-purity APIs and adhere to stringent Good Manufacturing Practices (GMP) required by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
• North America has limited bulk API manufacturing for lenalidomide. The focus in this region is more on finished dosage forms and formulation development, with API sourcing primarily from international suppliers.

WHO ARE THE KEY LENALIDOMIDE API MANUFACTURERS?

Several companies have established themselves as significant suppliers of lenalidomide API. Their market entry and production capacity are often linked to the patent landscape and the growth of the lenalidomide market.

Table 1: Key Lenalidomide API Manufacturers and Regions

Manufacturer Name	Primary Region	Regulatory Filings (Examples)	Notes
Natco Pharma Ltd.	India	US DMF, EDMF, WHO GMP	Significant producer for generic market entry.
Sun Pharmaceutical Industries Ltd.	India	US DMF, EDMF, WHO GMP	Large-scale production capabilities.
Dr. Reddy's Laboratories Ltd.	India	US DMF, EDMF, WHO GMP	Established API manufacturer with a broad portfolio.
Cipla Limited	India	US DMF, EDMF, WHO GMP	Vertically integrated API production.
Divi's Laboratories Limited	India	US DMF, EDMF	Known for high-volume synthesis and custom manufacturing.
Zhejiang Hisun Pharmaceutical Co., Ltd.	China	US DMF, EDMF	Major Chinese API producer with international reach.
Jiangsu Aosaikang Pharmaceutical Co., Ltd.	China	US DMF, EDMF	Focus on intermediates and APIs for oncology drugs.
Almac Group	Europe	US DMF, EDMF	Contract development and manufacturing organization (CDMO).
Polpharma Group	Europe	US DMF, EDMF	European manufacturer with API development and production.

Note: DMF refers to Drug Master File. EDMF refers to European Drug Master File. Specific filings may vary.

WHAT ARE THE REGULATORY CONSIDERATIONS FOR LENALIDOMIDE API SOURCING?

Sourcing lenalidomide API requires strict adherence to regulatory guidelines to ensure product quality, safety, and efficacy. Manufacturers must comply with Good Manufacturing Practices (GMP) as defined by major regulatory bodies.

• U.S. Food and Drug Administration (FDA): API manufacturers supplying the U.S. market must have their manufacturing facilities inspected and approved by the FDA. Submission of a Drug Master File (DMF) is standard practice, detailing the manufacturing process, controls, and specifications of the API.
• European Medicines Agency (EMA): For the European market, manufacturers typically file an Active Substance Master File (ASMF), formerly known as an European Drug Master File (EDMF). Compliance with EU GMP is mandatory.
• Other Regulatory Authorities: Manufacturers also seek approval from agencies in Japan (PMDA), Canada (Health Canada), Australia (TGA), and other significant markets, each with its own specific requirements.
• Quality Control and Testing: Rigorous analytical testing is required for identity, purity, potency, and impurity profiles. This includes testing for genotoxic impurities, which is critical for lenalidomide due to its mechanism of action.
• ICH Guidelines: Adherence to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines (e.g., ICH Q7 for GMP for APIs, ICH Q3A/B/C for impurities) is essential for global regulatory acceptance.

WHAT IS THE PATENT LANDSCAPE IMPACTING LENALIDOMIDE API SUPPLY?

The patent status of lenalidomide has significantly shaped its API supply chain, particularly regarding the entry of generic manufacturers.

• Composition of Matter Patent: The primary patent covering the lenalidomide molecule itself expired in many major markets. In the U.S., for example, key composition of matter patents expired around 2017-2020, depending on patent term extensions.
• Formulation and Method of Use Patents: While the molecule patent has expired, secondary patents related to specific formulations, dosing regimens, or methods of use may still be in effect or have expired more recently. These can influence market dynamics and generic entry strategies.
• Pediatric Exclusivity: In the U.S., pediatric exclusivity can extend market protection for a drug. Revlimid (lenalidomide) received an additional six months of pediatric exclusivity.
• Generic Entry: The expiration of key patents has opened the door for generic manufacturers to produce and market lenalidomide API and finished drug products. This has led to increased competition and a broader base of API suppliers.
• Litigation: The patent landscape has been subject to extensive litigation, particularly in the U.S., concerning patent challenges and the timing of generic market entry. These legal battles can impact the availability and pricing of lenalidomide API.

WHAT ARE THE KEY CHALLENGES IN SOURCING LENALIDOMIDE API?

Sourcing lenalidomide API involves navigating several complexities inherent in pharmaceutical manufacturing and global supply chains.

• Supply Chain Security and Traceability: Ensuring a secure and traceable supply chain is paramount. This involves qualifying suppliers, verifying the origin of raw materials, and implementing robust inventory management systems to prevent counterfeiting and diversion.
• Quality Assurance and Regulatory Compliance: Maintaining consistent API quality that meets stringent regulatory standards across different international markets is a continuous challenge. Changes in manufacturing processes, raw material suppliers, or regulatory requirements necessitate rigorous validation and re-qualification.
• Impurity Profiling and Control: Lenalidomide is a complex molecule. Manufacturers must have sophisticated analytical capabilities to identify, quantify, and control process-related impurities and degradation products, especially genotoxic impurities.
• Cost Management and Pricing Volatility: While generic competition typically drives down API prices, fluctuations in raw material costs, manufacturing overhead, and global demand can lead to price volatility. Sourcing strategies must account for these economic factors.
• Geopolitical and Environmental Factors: Global events, trade policies, and environmental regulations can disrupt manufacturing and logistics. Dependence on single geographic sources for critical raw materials or intermediates poses a risk.
• Intellectual Property Nuances: Even with primary patent expiration, navigating the residual IP landscape, including method-of-use patents and formulation patents, is crucial to avoid infringement.

WHAT ARE THE FUTURE TRENDS IN LENALIDOMIDE API SOURCING?

The lenalidomide API market is evolving, driven by ongoing patent expirations, market demand, and technological advancements.

• Increased Generic Competition: As more patents expire and regulatory approvals are granted, the market will see a greater number of generic lenalidomide API suppliers, intensifying price competition and potentially leading to consolidation among smaller players.
• Focus on Vertical Integration: Companies may pursue greater vertical integration, controlling the production of key intermediates to ensure supply chain stability and cost efficiency.
• Technological Advancements in Synthesis: Research into more efficient and environmentally friendly synthetic routes for lenalidomide API is likely to continue, potentially leading to lower manufacturing costs and reduced environmental impact.
• Enhanced Analytical Technologies: Advancements in analytical techniques will further improve the detection and control of impurities, leading to higher API quality standards.
• Diversification of Supply Chains: Pharmaceutical companies are increasingly looking to diversify their API sourcing to mitigate risks associated with geopolitical instability, natural disasters, or single-source dependencies. This may lead to a broader geographical distribution of manufacturing sites over time.
• Biologics and Biosimilars Influence: While lenalidomide is a small molecule, the broader trend towards biologics and biosimilars may indirectly influence API manufacturing technologies and regulatory approaches, though direct impact on small molecule API production is limited.

KEY TAKEAWAYS

• India and China are the dominant global sources for bulk lenalidomide API, driven by cost advantages and established manufacturing infrastructure.
• Regulatory compliance, particularly GMP certification and successful DMF submissions with the FDA and EMA, is critical for market access.
• The expiration of lenalidomide's primary composition of matter patents has facilitated significant generic API production and intensified market competition.
• Key challenges in sourcing include ensuring supply chain security, maintaining stringent quality control, managing impurity profiles, and navigating evolving intellectual property rights.
• Future trends point towards increased generic competition, potential vertical integration, advancements in synthesis technology, and a strategic diversification of supply chains to enhance resilience.

FAQS

1. What are the typical impurity profiles that manufacturers must control for lenalidomide API? Manufacturers must control process-related impurities (e.g., unreacted starting materials, by-products from synthetic steps) and degradation products. Specific attention is given to potential genotoxic impurities, given the therapeutic class of the drug. Regulatory bodies require detailed impurity profiling and stringent control strategies.

2. How does the patent expiry of lenalidomide impact the pricing of bulk API? Patent expiry typically leads to increased competition from generic manufacturers. This increased supply, coupled with competition among API producers, generally drives down the price of bulk lenalidomide API.

3. What is the significance of a Drug Master File (DMF) for lenalidomide API suppliers? A DMF is a submission to regulatory authorities (like the FDA) that contains confidential, detailed information about the facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. For lenalidomide API suppliers, a DMF is essential for their customers (finished drug product manufacturers) to reference in their drug applications, demonstrating the quality and regulatory compliance of the API.

4. Are there any regional specific quality requirements for lenalidomide API beyond general GMP? While GMP standards are globally harmonized to a degree through ICH guidelines, specific regional requirements can exist. For example, pharmacopoeial standards (e.g., USP, EP, JP) may have specific monographs for lenalidomide that dictate particular analytical tests or acceptance criteria. The EMA and FDA have specific expectations regarding the control of nitrosamine impurities in APIs, which would apply to lenalidomide if relevant.

5. What role does contract manufacturing play in the lenalidomide API supply chain? Contract Development and Manufacturing Organizations (CDMOs) play a significant role. Pharmaceutical companies, especially those focused on formulation and marketing, may outsource API synthesis to specialized CDMOs. These CDMOs often possess the expertise, capacity, and regulatory track record to efficiently produce complex APIs like lenalidomide, allowing brand and generic companies to focus on their core competencies.

CITATIONS

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-master-files [2] European Medicines Agency. (n.d.). Active Substance Master File (ASMF). Retrieved from https://www.ema.europa.eu/en/human-regulatory/research-and-development/scientific-guidelines/active-substance-master-file-asmf [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from https://www.ich.org/guidelines [4] U.S. Patent and Trademark Office. (n.d.). Patent Basics. Retrieved from https://www.uspto.gov/learning-and-resources/patent-and-trademark-rules/patent-basics [5] Multiple Generic Drug Approvals and Patent Litigation Filings related to Lenalidomide. (Information publicly available through court dockets and regulatory agency databases, e.g., FDA Orange Book, court records).